Navigation Links
ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease
Date:12/20/2007

PARIS, December 20 /PRNewswire-FirstCall/ -- ExonHit Therapeutics, a drug and diagnostic discovery company, announced today that it has obtained a regulatory approval to initiate a Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease. EHT 0202 is a compound, with a novel mechanism of action, which has shown benefits on memory and neuronal loss.

This will be the first Phase 2 clinical trial for EHT 0202, it will be a multi-center, double-blind trial, in which 135 patients will be randomized. The trial's primary endpoint is the safety and tolerability of the product when it is administered orally for a 3 month period in conjunction with an acetylcholinesterase inhibitor, the most common therapy used to treat Alzheimer's disease. The trial will also provide preliminary data on EHT 0202's clinical efficacy, in particular regarding its effects on cognition and behaviour.

Alzheimer's disease is a major public heath issue, with a patient population that is expected to grow rapidly in the near future because of the aging population. It is estimated that over 25 million people worldwide, including 860 thousand in France, suffer from Alzheimer's disease or assimilated pathologies. "Medical research has made significant progress in that field, as shown by the number of therapies now available, however their efficacy remains limited. There is thus a significant need for new and innovative therapies, which will not only provide symptomatic relief but also modify the disease's evolution by slowing or even stopping its underlying neurodegenerative process." stated Olivier Sol, MD, Clinical Director ExonHit.

"EHT 0202's pharmacological properties, linked to its GABA-A receptor modulating role, offer a promising approach to restoring the CNS processes that are altered in Alzheimer's disease, such as neuron degeneration and cognition. Indeed, this compound redirects the processing of APP (Amyloid Precursor Prot
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
4. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
5. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
6. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
7. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
8. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
9. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
10. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
11. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 According ... Market by Products (Consumables, Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, ... (Detection, Characterization) - Global Forecasts to 2019" ... is estimated at $896.5 Million in 2014 ... by 2019, growing at a CAGR of ...
(Date:7/28/2014)... PA & Boston, MA (PRWEB) July 28, 2014 ... collaboration agreements with two researchers to further develop potential ... deadly malignant brain tumor, in combination with their patented ... by ITI and Duke University, are based on the ... Chief, Division of Neurosurgery at The Preston Robert Tisch ...
(Date:7/28/2014)... 2014 Appistry, Inc. , a ... the power of genomics to next-generation medicine, announced today ... Challenge . , Two Appistry staff will be ... Center for Genome Resources, and Mr. Neil Miller, director ... Kansas City. Rounding out the panel are Appistry’s Dr. ...
(Date:7/28/2014)... July 28, 2014 The global market ... by 2020, according to a new study by Grand ... rising demand for effective vaccines and drugs in an ... medical needs is expected to drive market demand over ... enhance agricultural productivity via the use of genetically engineered ...
Breaking Biology Technology:Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4
... and for opening new food and beverage product categories ... 16 Frost & Sullivan, the international growth consulting ... 2008 North American Food and Beverage Probiotics Product Innovation ... strain, Ganeden BC30 (TM), for opening new development ...
... - The American Journal of Medicine , ... Medicine (AJM), one of Elsevier,s flagship health,sciences journals, has introduced ... forum where physicians and other,healthcare professionals can discuss the research ... Journal. , "The American ...
... Reduced Use of Chemicals Among Greatest Benefits , ... ... a few developing countries that have made significant progress in plant ... released, Dr. Elíbio Rech, a biotechnology researcher at Embrapa in Brazil, ...
Cached Biology Technology:Ganeden Biotech Receives Frost & Sullivan 'Probiotics Product Innovation' Award 2Ganeden Biotech Receives Frost & Sullivan 'Probiotics Product Innovation' Award 3Elsevier Introduces The American Journal of Medicine Blog 2Elsevier Introduces The American Journal of Medicine Blog 3New Online Video Features Brazilian Researcher Elbio Rech 2New Online Video Features Brazilian Researcher Elbio Rech 3
(Date:7/28/2014)... NEW YORK CITY (July 28, 2014)The Brain & ... its annual Klerman and Freedman Prizes, recognizing exceptional ... have been supported by NARSAD Young Investigator Grants. ... innovative ideas in neurobiological and psychosocial research for ... mental illnesses that affect one in four people. ...
(Date:7/28/2014)... suffer from fertility problems, many of these due to ... might expect such genes, which reduce an individual,s ability ... the Weizmann Institute of Science that recently appeared in ... riddle. Not only can it explain the high rates ... in understanding the causes of genetic diseases and their ...
(Date:7/27/2014)... nicotine and cotinine, a metabolite of nicotine, can potentially ... smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK is produced ... up in the tobacco smoke. Once inhaled, it is ... activated by a variety of enzymes called Cytochrome P450 ... can partially interfere with the activation of NNK, and ...
Breaking Biology News(10 mins):The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Mutations from Venus, mutations from Mars 2Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2
... new study from the University of Maryland School of Medicine ... of brain cells to communicate with each other. The study ... is caused and how it should be treated. Instead of ... such as serotonin, the scientists found that the transmission of ...
... , the functions of the three enzymes Tan, Ebony and ... involved in neurotransmitter recycling for the visual process. RUB researchers ... that flies cannot see without this recycling. Their analysis of ... function. Anna Ziegler, Florian Brsselbach and Bernhard Hovemann report in ...
... Marine biologists have, for the first time, found a whale ... into life in the sea depths. The discovery was made ... and includes the find of at least nine new species ... research, involving the University of Southampton, Natural History Museum, British ...
Cached Biology News:University of Maryland School of Medicine finds depression stems from miscommunication between brain cells 2University of Maryland School of Medicine finds depression stems from miscommunication between brain cells 3Blind flies without recycling 2Blind flies without recycling 3Antarctica's first whale skeleton found with nine new deep-sea species 2
... GI Number: 4503277 Accession ... Description: FUNCTION: Supplies the nucleotide substrate ... + H 2 O = dUMP ... SIMILARITY: Belongs to the Diseases: Benign ...
Active GST Protein...
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
DNA Purification...
Biology Products: